Intellia Therapeutics Inc (NTLA) Actualités

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to...

The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff...

Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NTLA

Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm...

Form 8-K - Current report

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading...

The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an...

The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an...

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading...

Form 8-K - Current report

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities